TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20683334
Drug: Sugammadex 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2.0 mg kg(‐1)
Study: 16180595
Drug: Daily stretch
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily stretch positioning for wrist and finger flexors and shoulder adductors and internal rotators, two 30-min stretches per day for up to 12 weeks post stroke.
Study: 12796526
Drug: Antipsychotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic therapy
Study: 8609746
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g single preoperative dose
Study: 25250613
Drug: Sitafloxacin 50
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sitafloxacin 50 mg
Study: 25250613
Drug: Sitafloxacin 100
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sitafloxacin 100 mg
Study: 25250613
Drug: Sitafloxacin 200
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sitafloxacin 200 mg
Study: 17548731
Drug: Intravenous cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cooling with 4 degrees C normal saline (500 to 2000 mL)
Study: 15562142
Drug: Aerosolized tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aerosolized tobramycin (300 mg twice daily for 6 months)
Study: 9539304
Drug: Ovine corticotropin-releasing
Normalized name: Ovine corticotropin-releasing factor
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovine corticotropin-releasing hormone (oCRH) 1 microg/kg body weight
Study: 9539304
Drug: Low-dose ACTH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ACTH 5 microg i.v.
Study: 1776334
Drug: molsidomine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: molsidomine (4 mg)
Study: 1776334
Drug: isosorbide‐5‐mononitrate (ISMN,
Approvals — FDA: no, EMA: no, PMDA: no
Description: isosorbide‐5‐mononitrate (ISMN, 20 mg)
Study: 30942510
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of saffron (two pills per day) for 3 months
Study: 30942510
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (two pills per day) for 3 months
Study: 20226444
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus leuprolide acetate (LA) placebo
Study: 16236177
Drug: Tigecycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline (100 mg initial dose, then 50 mg every 12 hours for 5 to 14 days)
Study: 16236177
Drug: Imipenem/cilastatin (500/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (500/500 mg every 6 hours or adjusted for renal dysfunction for 5 to 14 days)
Study: 11940029
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin Type A (BoNTA) intramuscular injections to triceps surae (800 U Dysport) and functional electrical stimulation (FES) of the common peroneal nerve with physiotherapy
Study: 2228399
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg dl-fenfluramine/meal
Study: 2228399
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg dl-fenfluramine/no meal
Study: 25707693
Drug: 3-antigen Staphylococcus
Normalized name: STAPHYLOCOCCUS EPIDERMIDIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-antigen Staphylococcus aureus vaccine (SA3Ag)
Study: 17451692
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (nonobese PCOS patients without insulin resistance)
Study: 15075548
Drug: AIDSVAX B/E
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIDSVAX B/E HIV vaccine trial participation
Study: 11158948
Drug: Acute ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute ascorbic acid treatment (2 g po)
Study: 11158948
Drug: Chronic ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic ascorbic acid treatment (500 mg/day for 1 month)
Study: 29512838
Drug: Stabilisation splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilisation splint treatment
Study: 27590017
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg PPS
Study: 27590017
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg PPS
Study: 23804582
Drug: Lifestyle change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle change with metformin
Study: 23804582
Drug: Lifestyle change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle change without metformin
Study: 20827195
Drug: Bortezomib-based chemotherapy
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib-based chemotherapy
Study: 20827195
Drug: Novel chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel chemotherapy agents
Study: 18983759
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 0.6 g + folic acid 500 microg/day
Study: 16025785
Drug: Intensive acupuncture
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive acupuncture treatment (10 sessions over 3-4 weeks)
Study: 16025785
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture treatment (control group)
Study: 8964646
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and lipid-lowering drugs
Study: 6113797
Drug: Meprobamate (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meprobamate (250 mg)
Study: 23769121
Drug: Control plus
Normalized name: SODIUM FLUORIDE 2.4 mg in 1 g DENTAL GEL, DENTIFRICE [AIM TARTAR CONTROL Plus Mouthwash and Whitening]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control plus HBO therapy
Study: 23769121
Drug: I/R plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: I/R plus HBO therapy
Study: 19403877
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg rhTSH/24-h interval
Study: 15476903
Drug: ProSorb diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProSorb diclofenac K 25 mg
Study: 15476903
Drug: ProSorb diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProSorb diclofenac K 50 mg
Study: 15476903
Drug: ProSorb diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProSorb diclofenac K 100 mg
Study: 11681767
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (7 mg/24 hours)
Study: 9603132
Drug: Topical soft
Normalized name: Della Soft Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical soft tissue lubricant
Study: 29458316
Drug: Energy-dense formulation
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-dense formulation (1.5 kcal/mL)
Study: 29458316
Drug: Routine enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine enteral feed formulation (1 kcal/mL)
Study: 9595924
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg by mouth from day 5 to day 24 of the menstrual cycle
Study: 9595924
Drug: Placebo 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10 mg by mouth from day 5 to day 24 of the menstrual cycle
Study: 8071049
Drug: Iopromide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopromide (300 mg I/kg)
Study: 8071049
Drug: Ioversol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ioversol (300 mg I/kg)
Study: 8071049
Drug: Iopamidol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol (300 mg I/kg)
Study: 2895662
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (bendrofluazide or propranolol)
Study: 24392599
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily insulin glargine (GL)
Study: 9175175
Drug: Powdered ginger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered ginger 4 g daily for 3 months
Study: 9175175
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of powdered ginger 10 g
Study: 9175175
Drug: Fenugreek 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenugreek 2.5 g twice daily for 3 months to healthy individuals
Study: 9175175
Drug: Fenugreek 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenugreek 2.5 g twice daily for 3 months to CAD patients with NIDDM
Study: 9175175
Drug: Fenugreek 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenugreek 2.5 g twice daily for 3 months to NIDDM (non-CAD) patients
Study: 9175175
Drug: Fenugreek 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenugreek 2.5 g twice daily for 3 months to severe NIDDM cases
Study: 9175175
Drug: Fenugreek administration
Normalized name: FENUGREEK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenugreek administration
Study: 8439216
Drug: Prolonged glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged glucose administration (250-300 g/day)
Study: 22481647
Drug: Nail lacquer
Normalized name: Penlac Nail Lacquer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nail lacquer containing ciclopirox 8% applied once weekly
Study: 20154483
Drug: Oral beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beclomethasone dipropionate (BDP) administration
Study: 18584525
Drug: Triple antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiviral induction therapy: amantadine hydrochloride and ribavirin, combined with 6 weeks interferon alfa‐2b (weeks 1‐2: 18 MU/day, weeks 3‐4: 9 MU/day, weeks 5‐6: 6 MU/day), thereafter combined with weekly peginterferon alfa‐2b
Study: 18584525
Drug: Treatment-naive patients
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-naive patients with HCV RNA <5 IU/mL at week 1 or 2
Study: 18584525
Drug: Treatment-naive patients
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-naive patients with HCV RNA >or=5 IU/mL at week 16
Study: 18584525
Drug: Previous non‐responders/relapsers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous non‐responders/relapsers with HCV RNA <5 IU/mL at week 2
Study: 18584525
Drug: Previous non‐responders/relapsers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous non‐responders/relapsers with HCV RNA >or=5 IU/mL at week 8
Study: 11059861
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin 200 mg/12 h for 7 days (group A)
Study: 11059861
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin 200 mg/12 h for 2 days followed by oral ciprofloxacin 500 mg/12 h for 5 days (group B)
Study: 9082266
Drug: Intravenous fentanyl-droperidol
Normalized name: droperidol / fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fentanyl-droperidol
Study: 8375123
Drug: Rectal morphine
Normalized name: morphine Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal morphine administration
Study: 31277165
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (3 cycles of combination therapy with carboplatin and nab‐paclitaxel)
Study: 27890714
Drug: Amikacin Fosfomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin Fosfomycin Inhalation System (AFIS) - 300 mg amikacin/120 mg fosfomycin, delivered by aerosol twice daily for 10 days (or to extubation if < 10 days) via the investigational eFlow Inline System.
Study: 27890714
Drug: Placebo (saline),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline), delivered by aerosol twice daily for 10 days (or to extubation if < 10 days) via the investigational eFlow Inline System.
Study: 27890714
Drug: Amikacin Fosfomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin Fosfomycin Inhalation System (AFIS)
Study: 15064259
Drug: 5-HT3 receptor
Normalized name: 5-HT3 receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT3 receptor antagonists combined with droperidol
Study: 15064259
Drug: 5-HT3 receptor
Normalized name: 5-HT3 receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT3 receptor antagonists combined with dexamethasone
Study: 15064259
Drug: 5-HT3 receptor
Normalized name: 5-HT3 receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT3 receptor antagonists alone
Study: 11192362
Drug: Metoprolol CR/XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/XL (200 mg once daily)
Study: 8478543
Drug: Traditional surveillance
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional surveillance system and monthly physician questionnaires
Study: 3823636
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg/kg body weight; equivalent to approximately 4 cups of coffee)
Study: 17020971
Drug: ZAP-70 positive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ZAP-70 positive CC genotypes
Study: 14617471
Drug: Ketamine general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine general anaesthesia with 0.6 mg atropine and 10 mg diazepam premedication
Study: 14617471
Drug: Ketamine general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine general anaesthesia with 0.6 mg atropine and 50 mg promethazine premedication
Study: 14617471
Drug: Ketamine general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine general anaesthesia with only 0.6 mg atropine
Study: 10081520
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg daily
Study: 9173652
Drug: Normovolemic haemodilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normovolemic haemodilution with Ringer solution
Study: 28044450
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg theanine
Study: 28044450
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg caffeine + 200 mg theanine
Study: 28044450
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg caffeine + 0 mg theanine (placebo)
Study: 24912486
Drug: Conventional oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oxygen therapy (OT)
Study: 19687032
Drug: Remifentanil (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (Group R) - continuous infusion titrated between 3 and 4 ng ml‐1
Study: 19687032
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (Group M) - i.v. bolus of 50 mg kg‐1 followed by a 15 mg kg‐1 h ‐1 continuous infusion
Study: 17490862
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 to 2550 mg daily)
Study: 2097486
Drug: Thiopental (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (300 mg)
Study: 30612325
Drug: Probiotic supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplements for 4 months
Study: 30612325
Drug: Placebo supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplements for 4 months
Study: 26978327
Drug: Memantine ER
Normalized name: memantine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine ER (3 to 15 mg/day based on body weight)
Study: 25982134
Drug: Fibrinogen concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen concentrate (30 mg kg(‐1)) with FIBTEM MCF trigger <13 mm (early substitution)
Study: 25982134
Drug: Fibrinogen concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen concentrate (30 mg kg(‐1)) with FIBTEM MCF trigger <8 mm (conventional)
Study: 25982134
Drug: Fibrinogen concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen concentrate (30 mg kg(‐1))
Study: 19877063
Drug: alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: alendronate (10 mg/day)
Study: 11778119
Drug: Sufentanil (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (intravenous and epidural)
Study: 11778119
Drug: Sufentanil in
Normalized name: sufentanil Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil in combination with local anaesthetics (ropivacaine, bupivacaine)
Study: 11778119
Drug: Sufentanil with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil with adjuvant drugs (clonidine, ketamine, adrenaline)
Study: 11778119
Drug: Various administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Various administration methods (PCA, PCEA, fixed intervals doses, continuous infusion)
Study: 9233591
Drug: Ifosphamide, etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosphamide, etoposide and epirubicin (IVE) plus G-CSF
Study: 9233591
Drug: Cyclophosphamide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide plus G-CSF
Study: 8121964
Drug: Placebo substitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo substitution after Vitamin E treatment
Study: 3117864
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (metered-dose inhaler, 2 mg, four times a day, or capsules, 20 mg, four times a day)
Study: 29285796
Drug: Weight-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based treatment (0.3 g/kg body weight)
Study: 29285796
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (15 g for adults, 10 g for children)
Study: 25281992
Drug: Aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole once-monthly 400mg
Study: 25281992
Drug: Aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole once-monthly 50mg
Study: 23471546
Drug: Mirabegron 25
Normalized name: mirabegron 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 25 mg QD
Study: 23471546
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg QD
Study: 23471546
Drug: Mirabegron 100
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron 100 mg QD
Study: 23471546
Drug: Mirabegron 200
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron 200 mg QD
Study: 23471546
Drug: Mirabegron (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (all doses)
Study: 23471546
Drug: Mirabegron 100
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron 100 mg and 200 mg
Study: 20855387
Drug: Hypothermia group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia group (rectal temperature of 33.5°C for 72 hours)
Study: 20855387
Drug: Normothermia group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermia group (rectal temperature of 37°C)
Study: 12398952
Drug: High-calcium milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calcium milk powder (800 mg of calcium)
Study: 1722834
Drug: Honvan (diethylstilbestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honvan (diethylstilbestrol diphosphate) 300 mg/day
Study: 1722834
Drug: Estracyt (estramustine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estracyt (estramustine phosphate) 560 mg/day
Study: 1722834
Drug: Prostal (chlormadinone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostal (chlormadinone acetate) 100 mg/day
Study: 1722834
Drug: Castration plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Castration plus MTX (methotrexate) 20 mg/m2 every 2 weeks
Study: 1722834
Drug: Castration plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Castration plus CPM (cyclophosphamide) 0.5-1 g/m2 every 3-4 weeks
Study: 29348711
Drug: Topical ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ciprofloxacin ear drops plus oral placebo
Study: 29348711
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral and topical ciprofloxacin
Study: 24243927
Drug: Isotonic nasal
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotonic nasal saline spray
Study: 18756344
Drug: Pentoxifylline 200
Normalized name: pentoxifylline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 200 mg per day for three days
Study: 12806591
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 16 mg + Lisinopril 20 mg
Study: 12806591
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg (maximum recommended dose)
Study: 8840293
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (new model of hemodialysis potassium removal)
Study: 8840293
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (standard hemodialysis)
Study: 1611114
Drug: 1.3 g
Normalized name: glycerin 1.3 g RECTAL SUPPOSITORY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3 g ethoglucid
Study: 6560416
Drug: Technique 1
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technique 1 for administering subcutaneous low-dose heparin